Compare Amphastar Pharmaceuticals Inc (AMPH) vs Logitech International SA (LOGI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Logitech International SA — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Logitech International SA trades at $102 (market cap $14.65B). The key difference: Logitech International SA is far larger — about 17.7× Amphastar Pharmaceuticals Inc's market cap, and Logitech International SA pays a 1.67% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | LOGI | |
|---|---|---|
Market Cap | $826.08M | $14.65B |
Sector | Health | Technology |
52-Week High | $30.81 | $126.69 |
52-Week Low | $16.87 | $85.84 |
Enterprise Value | $1.22B | $13.00B |
Dividend Yield | — | 1.67% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Logitech (LOGI) trades at $101.95, up 0.28% on the day, with a bullish technical signal despite mixed moving averages. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $1.13 exceeding the $1.10 estimate. Fundamentals show robust profitability, including a 43.2% gross margin and 32.78% ROE, while valuation ratios like P/E of 21.25 and P/S of 3.12 reflect moderate pricing. Recent news highlights partnerships, such as with Call of Duty: Modern Warfare 4, and product launches like the G3 Series, supporting growth momentum.
The outlook for LOGI is cautiously optimistic, with a consensus price target of $113.00 implying 11% upside. Opportunities include B2B expansion and AI-enabled products driving margin growth, but risks involve competitive pressures in peripherals and reliance on consumer spending. Analyst sentiment is divided, with 26% buy ratings balanced by equal sell recommendations, indicating uncertainty amid solid execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
